S
S Ferraro
Researcher at University of Pisa
Publications - 18
Citations - 293
S Ferraro is an academic researcher from University of Pisa. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 12 publications receiving 141 citations.
Papers
More filters
Journal ArticleDOI
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
Marco Tuccori,S Ferraro,I Convertino,E Cappello,G Valdiserra,Corrado Blandizzi,Fabrizio Maggi,Daniele Focosi +7 more
TL;DR: In this paper, the authors focus on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials.
Journal ArticleDOI
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
Marco Tuccori,I Convertino,S Ferraro,E Cappello,G Valdiserra,Daniele Focosi,Corrado Blandizzi +6 more
TL;DR: The rationale behind the claims for use of these drugs in COVID-19, the communication about their effects on the disease, the consequences of this communication on people’s behavior, and the responses of some influential regulatory authorities are analyzed in an attempt to minimize the actual or potential risks arising from this behavior are analyzed.
Journal ArticleDOI
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.
TL;DR: The potential advantages of the most promising pharmacological approaches to improve prognosis and quality of care in Sars-CoV-2 complications are discussed.
Journal ArticleDOI
The usefulness of listening social media for pharmacovigilance purposes: a systematic review
TL;DR: Proto-signals identified by social media listening had the potential of anticipating pre-specified known signals in only six studies, and the personal perception of patients reported in social media could be used to implement effective risk communication strategies.
Journal ArticleDOI
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.
TL;DR: Bamlanivimab, developed from human convalescent plasma, was the first monoclonal antibody to become available for emergency use in several countries in the COVID-19 pandemic emergency as mentioned in this paper.